Secondary causes of nonalcoholic fatty liver disease

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 3, 2012, Pages 199-207

  Kneeman, Jacob M ^a   Misdraji, Joseph ^a   Corey, Kathleen E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Fatty liver; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Secondary causes

Indexed keywords

AMIODARONE; ANTIDIABETIC AGENT; CHYLOMICRON; CORTICOSTEROID; DIDANOSINE; FIALURIDINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN; METFORMIN; METHOTREXATE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAMOXIFEN; VERY LOW DENSITY LIPOPROTEIN; VITAMIN; ZIDOVUDINE;

ABETALIPOPROTEINEMIA; CELIAC DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; EUROPE; FAMILIAL HYPERLIPEMIA; FAMILIAL HYPOBETALIPOPROTEINEMIA; FATTY LIVER; GLYCOGEN STORAGE DISEASE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INSULIN RESISTANCE; JEJUNOILEAL BYPASS; LIPODYSTROPHY; LIVER CIRRHOSIS; LIVER INJURY; LOW FAT DIET; NONALCOHOLIC FATTY LIVER; NUTRITIONAL DISORDER; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STARVATION; TOTAL PARENTERAL NUTRITION; UNITED STATES; VIRUS HEPATITIS; VITAMIN SUPPLEMENTATION; WEBER CHRISTIAN PANNICULITIS; WEIGHT REDUCTION; WILSON DISEASE;

EID: 84860504360     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11430859     Document Type: Review

References (40)

1. Abdo A. Meddings J. Swain M. (2004) Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2: 107–112.
2. Allard J.P. (2002) Other disease associations with non-alcoholic fatty liver disease (NAFLD). Best Pract Res Clin Gastroenterol 16: 783–795.
3. Angulo P. (2007) GI epidemiology: nonalcoholixc fatty liver disease. Aliment Pharmacol Therapeut 25: 883–889.
4. Assmann G. Seedorf U. Milunsky A. Milunsky K. (2001) Acid lipase deficiency: Wolman disease and cholesterol ester storage disease. In: Sciver, Beuadet, Sly and Valle, The Metabolic and Molecular Bases of Inherited Disease New York: McGraw-Hill, pp. 3551–3572.
5. Badaloo A. Reid M. Soares D. Forrester T. Jahoor F. (2005) Relation between liver fat content and the rate of VLDL apolipoprotein B-100 synthesis in children with protein-energy malnutrition. Am J Clin Nutr 81: 1126–1132.
6. Brown A.J. (2008) Viral hepatitis and fatty liver disease: how an unwelcome guest makes pate of the host. Biochemical J 416 (2): e15–e17.
7. Bruno S. Maisonneuve P. Castellana P. Rotmensz N. Rossi S. Maggioni M. et al. (2005) Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ (Clin Res Ed) 330: 932.
8. Burkhead J.L. Gray L.W. Lutsenko S. (2010) Systems biology approach to Wilson's disease. Biometals 24 (3): 455–456; 575
9. Burwinkel B. Rootwelt T. Kvittingen E.A. Chakraborty P.K. Kilimann M.W. (2003) Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in the PHKG 2 gene. Pediatric Res 54: 834–839.
10. Cai W. Wu J. Hong L. Xu Y. Tang Q. Shi C. (2006) Oxidative injury and hepatocyte apoptosis in total parenteral nutrition-associated liver dysfunction. J Pediatric Surg 41: 1663–1668.
11. Crum Cianflone N. Dilay A. Collins G. Asher D. Campin R. Medina S. et al. (2009) Nonalcoholic fatty liver disease among HIV-infected persons. JAIDS 50: 464–473.
12. Day C.P. (2011) Non-alcoholic fatty liver disease: a massive problem. Clin Med 11: 176–178.
13. de Bruin T.W.A. Georgieva A.M. Brouwers M.C.G.J. Heitink M.V. van der Kallen C.J.H. van Greevenbroek M.M.J. (2004) Radiological evidence of nonalcoholic fatty liver disease in familial combined hyperlipidemia. Am J Med 116: 847–849.
14. Farinati F. Cardin R. D'Inca R. Naccarato R. Sturniolo G.C. (2003) Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease. J Lab Clin Med 141: 372–377.
15. Gan S.K. Watts G.F. (2008) Is adipose tissue lipolysis always an adaptive response to starvation?: implications for non-alcoholic fatty liver disease. Clin Sci 114: 543–545.
16. Guigui B. Perrot S. Berry J.P. Fleury-Feith J. Martin N. Metreau J.M. et al. (1988) Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 8: 1063–1068.
17. Harada N. Soejima Y. Taketomi A. Yoshizumi T. Uchiyama H. Ikegami T. et al. (2009) Recurrent familial hypobetalipoproteinemia-induced nonalcoholic fatty liver disease after living donor liver transplantation. Liver Transplant 15: 806–809.
18. Herranz P. de Lucas R. Pérez-España L. Mayor M. (2008) Lipodystrophy syndromes. Dermatol Clin 26 (4).
19. Igal R.A. Coleman R.A. (1998) Neutral lipid storage disease: a genetic disorder with abnormalities in the regulation of phospholipid metabolism. J Lipid Res 39: 31–43.
20. Jia Y. Viswakarma N. Fu T. Yu S. Rao M.S. Borensztajn J. et al. (2009) Conditional ablation of mediator subunit MED 1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis. Gene Expression 14: 291–306.
21. Kennedy R.J. Murphy L.R. (1949) Weber–Christian disease. Am J Med 6: 672–680.
22. Kishnani P.S. Austin S.L. Arn P. Bali D.S. Boney A. Case L.E. et al. (2010) Glycogen storage disease type III diagnosis and management guidelines. Genetics Med 12: 446–463.
23. Langman G. Hall P.M. Todd G. (2001) Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury. J Gastroenterol Hepatol 16: 1395–1401.
24. Lewis J.H. Zimmerman H.J. (1989) Drug-induced liver disease. Med Clin N Am 73: 775–792.
25. Linton M.F. Farese R.V. Jr Young S.G. (1993) Familial hypobetalipoproteinemia. J Lipid Res 34: 521–541.
26. Ludvigsson J.F. Elfstrom P. Broome U. Ekbom A. Montgomery S.M. (2007) Celiac disease and risk of liver disease: a general population-based study. Clin Gastroenterol Hepatol 5: 63–69.e1.
27. McCullough A.J. Fleming C.R. Thistle J.L. Baldus W.P. Ludwig J. McCall J.T. et al. (1983) Diagnosis of Wilson's disease presenting as fulminant hepatic failure. Gastroenterology 84: 161–167.
28. Muntoni S. Wiebusch H. Jansen-Rust M. Rust S. Seedorf U. Schulte H. et al. (2007) Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol 27: 1866–1868.
29. Muraca M. Gerunda G. Neri D. Vilei M.T. Granato A. Feltracco P. et al. (2002) Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 359: 317–318.
30. Neuschwander-Tetri B.A. (2005) Nonalcoholic steatohepatitis and the metabolic syndrome. Am J Med Sci 330: 326–335.
31. Pillai A.A. Rinella M.E. (2009) Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis 13: 689–710.
32. Price J.C. Thio C.L. (2010) Liver disease in the HIV-infected individual. Clin Gastroenterol Hepatol 8: 1002–1012.
33. Ratziu V. Bellentani S. Cortez-Pinto H. Day C. Marchesini G. (2010) A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 53: 372–384.
34. Reddy S.K. Kishnani P.S. Sullivan J.A. Koeberl D.D. Desai D.M. Skinner M.A. et al. (2007) Resection of hepatocellular adenoma in patients with glycogen storage disease type Ia. J Hepatol 47: 658–663.
35. Rubenfire M. Brook R.D. Rosenson R.S. (2010) Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 123: 892–898.
36. Sanyal A.J. Brunt E.M. Kleiner D.E. Kowdley K.V. Chalasani N. Lavine J.E. et al. (2011) Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 54: 344–353.
37. Saphner T. Triest-Robertson S. Li H. Holzman P. (2009) The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 115: 3189–3195.
38. Steindl P. Ferenci P. Dienes H. Grimm G. Pabinger I. Madl C. et al. (1997) Wilson's disease in patients presenting with liver disease: A diagnostic challenge. Gastroenterology 113: 212–218.
39. Wasserman J.M. Thung S.N. Berman R. Bodenheimer H.C. Jr Sigal S.H. (2001) Hepatic Weber–Christian disease. Seminars Liver Dis 21: 115–118.
40. Zeissig S. Dougan S.K. Barral D.C. Junker Y. Chen Z. Kaser A. et al. (2010) Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD 1 function. J Clin Investigation 120: 2889–2899.